Results 91 to 100 of about 18,201 (186)
Systematic review (51 studies; 547 patients) indicates dupilumab may unmask/worsen CTCL (mainly MF/SS). A French Delphi consensus recommends rigorous diagnostic workup, avoiding dupilumab in confirmed CTCL, discontinuing upon diagnosis, and favouring methotrexate or phototherapy.
Florent Amatore +8 more
wiley +1 more source
Pulmonary Mucoepidermoid Carcinoma With Multiple Paraneoplastic Syndromes. [PDF]
Tay SB, Al Jajeh I, Lee LAL, Lee L.
europepmc +1 more source
International Journal of Rheumatic Diseases, Volume 29, Issue 8, August 2026.
Yoshinori Taniguchi, Daiki Okada
wiley +1 more source
Altered exosomal miRNA profiles in patients with paraneoplastic cerebellar degeneration
Objective Patients with ovarian cancer (OC) may develop anti‐Yo‐associated paraneoplastic cerebellar degeneration (PCD)—a cerebellar ataxia associated with tumor‐induced autoimmunity against CDR2 and CDR2L proteins.
Eirik Tveit Solheim +7 more
doaj +1 more source
Correction to: Dual paraneoplastic syndromes in a patient with small cell lung cancer: a case report. [PDF]
Conners K, Woods SE, Webb M.
europepmc +1 more source
Paraneoplastic Syndromes in Neuro-Ophthalmology. [PDF]
Hickman SJ.
europepmc +1 more source
Single-Center Retrospective Analysis of Paraneoplastic Syndromes with Peripheral Nerve Damage. [PDF]
Tian J +8 more
europepmc +1 more source
Multiple Paraneoplastic Syndromes [PDF]
A F, Broomhead +2 more
openaire +2 more sources
Clinical characteristics of paraneoplastic syndromes in patients with head and neck cancer. [PDF]
Diao W +8 more
europepmc +1 more source

